[Phospholipase A2 inhibitors in hemorrhagic-necrotizing pancreatitis. Animal experiment evaluation of a new treatment concept].
In mongrel dogs with induced pancreatitis we studied the effects of the nonspecific phospholipase A2-inhibitors chlorpromazine, gabexate mesilate and CaNa2EDTA on the course of pancreatogenic shock and the intrapancreatic lysolecithin production. The local level of lysolecithine the metabolite of phospholipase A2 was lower in the treated than in the untreated control groups. Gabexate mesilate was the most active inhibitor. However, none of the drugs had a beneficial influence on hemodynamics, chlorpromazine made it even worse. Morphologically no difference was seen between the treated and untreated groups.
D000208:Acute Disease; D000818:Animals; D002746:Chlorpromazine / Q000627:therapeutic use; D004285:Dogs; D004492:Edetic Acid / Q000627:therapeutic use; D005260:Female; D016670:Gabexate; D006146:Guanidines / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects; D006470:Hemorrhage / Q000188:drug therapy; D008244:Lysophosphatidylcholines / Q000378:metabolism; D008297:Male; D009336:Necrosis; D010195:Pancreatitis / Q000188:drug therapy*; D010740:Phospholipases / Q000037:antagonists & inhibitors*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2
D006146:Guanidines; D008244:Lysophosphatidylcholines; D016670:Gabexate; D004492:Edetic Acid; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2; D002746:Chlorpromazine
Phospholipase A2-Inhibitoren bei hämorrhagisch-nekrotisierender Pankreatitis. Tierexperimentelle Uberprüfung eines neuen Behandlungskonzeptes.